iCapital® Names New Marketing Leadership to Drive Global Growth tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology
News provided by
Share this article
Share this article
LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement.
Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their therapeutic vaccine clinical trials, and provide technical and clinical support to NEUVOGEN s development teams. ImaginAb will receive license fees and other contingent payments. No other terms were disclosed.